Evolent Health, Inc. (EVH)
| Market Cap | 387.39M -66.8% |
| Revenue (ttm) | 1.88B -26.6% |
| Net Income | -579.40M |
| EPS | -5.07 |
| Shares Out | 111.64M |
| PE Ratio | n/a |
| Forward PE | 20.22 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,862,147 |
| Open | 3.080 |
| Previous Close | 3.130 |
| Day's Range | 3.080 - 3.610 |
| 52-Week Range | 2.095 - 12.065 |
| Beta | 0.37 |
| Analysts | Strong Buy |
| Price Target | 7.93 (+128.53%) |
| Earnings Date | May 7, 2026 |
About EVH
Evolent Health, Inc., through its subsidiary, provides specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company offers integrated value-based care platform for health plan administration and management. It also provides administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, an... [Read more]
Financial Performance
In 2025, Evolent Health's revenue was $1.88 billion, a decrease of -26.56% compared to the previous year's $2.55 billion. Losses were -$579.40 million, 520.0% more than in 2024.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for EVH stock is "Strong Buy." The 12-month stock price target is $7.93, which is an increase of 128.53% from the latest price.
News
Evolent To Release First Quarter 2026 Financial Results on Thursday, May 7, 2026
WASHINGTON, April 7, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release it...
Evolent announces appointment of Archie Mayani as chief product officer
Industry veteran brings track record of innovation from GHX, Change Healthcare, UnitedHealth Group and Amazon. WASHINGTON, March 19, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company fo...
Evolent Health Transcript: Oppenheimer 36th Annual Healthcare MedTech & Services Conference
Smooth client implementations and conservative financial guidance set the stage for sequential EBITDA growth, with a strong pipeline and focus on risk-aligned products. Deleveraging and profitability are top priorities, while AI and clinical differentiation support long-term growth.
Evolent to Participate in Upcoming Investor Conferences
WASHINGTON, Feb. 26, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced that members of it...
Evolent Health Earnings Call Transcript: Q4 2025
Q4 2025 results exceeded guidance, with strong revenue and EBITDA growth driven by oncology and new contracts. 2026 guidance projects 30% revenue growth, margin expansion, and significant cost savings, despite exchange headwinds and conservative reserving for new business.
Evolent Announces Fourth Quarter 2025 Results and Full Year 2025 Results
WASHINGTON, Feb. 24, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through...
Evolent To Release 2025 Fourth Quarter and Year-End Financial Results on Tuesday, February 24, 2026
WASHINGTON, Feb. 4, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its...
Evolent Reports Inducement Award Under NYSE Listing Rule 303A.08
WASHINGTON, Jan. 2, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through ...
Evolent Health Transcript: Piper Sandler 37th Annual Healthcare Conference
Specialty care management trends remain stable, with new contract protections and a focus on evidence-based pathways driving both quality and cost savings. Financial guidance for 2025 and 2026 reflects growth in new contracts, efficiency gains, and strategic divestiture, with capital allocated to debt reduction.
Evolent Health Earnings Call Transcript: Q3 2025
Q3 results exceeded expectations with strong revenue and EBITDA growth, driven by new contract wins and enhanced contract structures. 2026 revenue under contract is $2.5B, but EBITDA growth is uncertain due to potential membership declines in key markets.
Evolent and American Oncology Network unveil innovative model seeking to improve cancer care while eliminating prior authorization burden
WASHINGTON , Nov. 6, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, and American Oncology Network (AON...
Evolent Announces Third Quarter 2025 Results
Q3 2025 financial results ahead of expectations. Announces more than $500 million in newly-contracted annualized revenue to launch in 2026.
Evolent To Release Third Quarter 2025 Financial Results on Thursday, November 6, 2025
Company to Participate in Upcoming Conferences WASHINGTON , Oct. 9, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex...
Evolent Announces Strategic Divestiture of its Value-Based Primary Care Business, Evolent Care Partners
Transaction enhances focus on specialty condition management and accelerates Evolent's deleveraging path. Proceeds from the transaction to be used to prepay senior term debt; Immediately accretive to ...
Evolent Health, Inc. Announces Pricing of Oversubscribed and Upsized $145.0 Million of Convertible Senior Notes Due 2031 to Repurchase Existing Notes and Class A Common Stock
WASHINGTON , Aug. 19, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions ("Evolent"), today announced the p...
Evolent Health, Inc. Announces Proposed Offering of $140.0 Million of Convertible Senior Notes Due 2031 to Repurchase Existing Notes and Class A Common Stock
WASHINGTON , Aug. 18, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions ("Evolent"), today announced that ...
Evolent Health Transcript: Canaccord Genuity’s 45th Annual Growth Conference
EBITDA outperformance led to raised guidance, while revenue was adjusted due to contract timing. Major partnerships, robust pipeline, and AI-driven efficiencies support confidence in 2025 targets. Cash flow normalizes after one-time items, with a focus on deleveraging.
Evolent Health Earnings Call Transcript: Q2 2025
Q2 adjusted EBITDA exceeded expectations, with strong new business momentum and a robust pipeline, especially in Medicare Advantage. AI initiatives are driving efficiency, and 2026 revenue is projected to surpass $2.5 billion, despite exchange headwinds.
Evolent Announces Second Quarter 2025 Results
WASHINGTON , Aug. 7, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through...
Evolent To Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025
Company to Participate in Upcoming Conferences WASHINGTON , July 14, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with comple...
Evolent announces key appointments to leadership team
Dr. David Lim joins Evolent as chief clinical officer John Way joins Evolent as CFO, Performance Suite WASHINGTON , July 9, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on ...
Evolent reiterates Q2 and full year guidance for Adjusted EBITDA
Notes accelerating 2026 revenue bookings forecast Secures incremental non-dilutive financing WASHINGTON , June 20, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving...
Evolent Health Transcript: 45th Annual William Blair Growth Stock Conference
Despite recent market headwinds, demand and pipeline activity have surged, with a strong long-term growth outlook and a $150 billion addressable market. The company’s solutions improve care quality and reduce costs, with innovation in clinical support, provider alignment, and patient navigation driving both financial and clinical outcomes.
Evolent Health Earnings Call Transcript: Q1 2025
Q1 2025 results exceeded expectations, driven by new contracts, strong renewals, and robust demand across all segments. Oncology trends were favorable, and guidance for 2025 is unchanged, with significant growth potential and ongoing efficiency gains from AI and automation.
Evolent Announces First Quarter 2025 Results
WASHINGTON , May 8, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through ...